Physician profile
Eric Norell
NPI 1902961824
$7,378.93
in general payments reported to CMS, 2019-2025
29 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,445 · 2020: $276 · 2021: $692 · 2022: $865 · 2023: $826 · 2024: $1,267 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,083 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,082.67 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,652.71 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $870.51 | 2022-2025 | Infuse, Biotrue, Vyzulta |
| Alcon Vision LLC | $700.85 | 2019-2025 | Eysuvis, Precision 1, Rocklatan |
| Mallinckrodt Hospital Products INC. | $495.52 | 2021-2025 | Acthar |
| Oyster Point Pharma, INC. | $319.90 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Astellas Pharma US INC | $209.23 | 2024-2025 | Izervay |
| Harrow Eye, LLC | $199.92 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $195.64 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $190.14 | 2022-2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa, Istent Trabecular Micro-Bypass System Model Is3 |
| Novartis Pharmaceuticals Corporation | $188.15 | 2019-2023 | |
| Coopervision INC. | $183.71 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Paragon Crt |
| Lkc Technologies, INC. | $142.33 | 2024-2025 | |
| Abbvie INC. | $137.22 | 2022-2024 | |
| Kala Pharmaceuticals, INC. | $114.63 | 2021-2022 | |
| Genentech USA, INC. | $96.50 | 2022-2025 | Vabysmo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $86.77 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $76.42 | 2021-2024 | Cequa |
| Apellis Pharmaceuticals, INC. | $74.10 | 2023-2025 | Syfovre |
| Allergan, INC. | $73.10 | 2020-2022 | |
| Shire North American Group INC | $72.25 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $62.42 | 2019-2022 | |
| Thea Pharma INC. | $56.00 | 2023-2025 | Iyuzeh |
| Maculogix, INC. | $36.08 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $35.91 | 2024-2025 | Eylea Hd |
| Amgen INC. | $32.51 | 2025 | Tepezza |
| Dompe US, INC. | $22.58 | 2024 | Oxervate |
| Horizon Therapeutics Plc | $20.90 | 2021 | |
| Quidel Corporation | $19.94 | 2019 | |
| Aerie Pharmaceuticals, INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Norell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.